Arcellx (ACLX) Shares Outstanding (Diluted Average) (2021 - 2025)
Arcellx (ACLX) recorded quarterly Shares Outstanding (Diluted Average) of $56.3 million in Q4 2025, little changed quarter-over-quarter from $56.6 million in Q3 2025, and up 5.11% on a YoY basis from $53.6 million in Q4 2024.
Arcellx (ACLX) Shares Outstanding (Diluted Average) (2021 - 2025) Analysis & Trends
Arcellx's Shares Outstanding (Diluted Average) history runs 5 years deep, the most recent figure standing at $56.3 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Diluted Average) rose 5.11% year-over-year to $56.3 million; the TTM figure through Dec 2025 stood at $56.3 million (up 5.11% YoY), while the FY2025 annual figure was $56.3 million, up 5.11% from the prior year.
- Shares Outstanding (Diluted Average) was $56.3 million for Q4 2025 at Arcellx, roughly flat from $56.6 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $56.6 million in Q3 2025 to a low of $337302.0 in Q1 2021.
- Historically, Shares Outstanding (Diluted Average) has averaged $37.4 million across 5 years, with a median of $47.6 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Diluted Average) surged 8044.59% in 2022, then climbed 4.74% in 2025.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $446379.0 in 2021, then soared by 8044.59% to $36.4 million in 2022, then soared by 32.2% to $48.1 million in 2023, then increased by 11.45% to $53.6 million in 2024, then gained by 5.11% to $56.3 million in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $56.3 million (Q4 2025), $56.6 million (Q3 2025), and $56.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 56.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 56.31 Mn |
| Sep 30, 2025 | 56.59 Mn |
| Jun 30, 2025 | 56.22 Mn |
| Mar 31, 2025 | 55.26 Mn |
| Dec 31, 2024 | 53.57 Mn |
| Sep 30, 2024 | 53.37 Mn |
| Jun 30, 2024 | 53.52 Mn |
| Mar 31, 2024 | 52.76 Mn |
| Dec 31, 2023 | 48.06 Mn |
| Sep 30, 2023 | 47.78 Mn |
| Jun 30, 2023 | 47.44 Mn |
| Mar 31, 2023 | 46.77 Mn |
| Dec 31, 2022 | 36.36 Mn |
| Sep 30, 2022 | 33.81 Mn |
| Jun 30, 2022 | 28.73 Mn |
| Mar 31, 2022 | 20.76 Mn |
| Dec 31, 2021 | 446,379.00 |
| Sep 30, 2021 | 422,825.00 |
| Jun 30, 2021 | 437,258.00 |
| Mar 31, 2021 | 337,302.00 |